Reduced cardiac side-effect potential by introduction of polar groups: discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples